Cancer Family
Intestinal Neoplasm
CI-CAN-00000209Explore in graph →
Non-malignant1,892 active trials21 approved drugs383 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000209Explore in graph →
Clinical trials
9,155 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07752875 | A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation | not yet recruiting | Phase 1 / Phase 2 | 250 | LG ChemINDUSTRY | 0 | Aug 7, 2026 | clinicaltrials |
| NCT02965703 | Aspirin in Preventing Colorectal Cancer in Patients With Colorectal Adenoma | active not recruiting | Phase 2 | 81 | National Cancer Institute (NCI)NIH | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07750041 |
| A Phase Ib/II Study of SYS6090 Combination Therapy in Advanced Colorectal Cancer |
| not yet recruiting |
| Phase 1 / Phase 2 |
| 260 |
| CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY |
| 1 |
| Aug 6, 2026 |
| clinicaltrials |
| NCT07209215 | ctDNA-Informed Management of Early-Stage Rectal Cancer(ULTIMATE) | not yet recruiting | Phase 2 | 200 | University of California, DavisOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT04083599 | GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 350 | GenmabINDUSTRY | 12 | Aug 4, 2026 | clinicaltrials |
| NCT05111574 | Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery | active not recruiting | Phase 2 | 101 | National Cancer Institute (NCI)NIH | 2 | Aug 4, 2026 | clinicaltrials |
| NCT07737600 | A Study of MRG007 Combination Therapy for Advanced Colorectal Cancer | not yet recruiting | Phase 1 / Phase 2 | 316 | Lepu Biopharma Co., Ltd.INDUSTRY | 1 | Aug 4, 2026 | clinicaltrials |
| NCT06210971 | Neoadjuvant Chemoradiation With Nal-IRI and Capecitabine Guided by UGT1A1 Status in Patients With Rectal Cancer | active not recruiting | Phase 2 | 60 | Hebei Medical University Fourth HospitalOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT06949098 | Tumor Local Excision +Postoperative Adjuvant Chemoradiotherapy for T1-2N0M0 Low/Ultra-Low Rectal Cancer | recruiting | Phase 2 | 60 | Hebei Medical University Fourth HospitalOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT06949111 | Radiotherapy + Systemic Therapy as Conversion Therapy for pMMR/MSS T4M0 Colon Cancer（Neo-Color） | recruiting | Phase 2 | 128 | Hebei Medical University Fourth HospitalOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT07397338 | Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors | recruiting | Phase 1 / Phase 2 | 370 | Revolution Medicines, Inc.INDUSTRY | 1 | Aug 3, 2026 | clinicaltrials |
| NCT02888743 | Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer | active not recruiting | Phase 2 | 110 | National Cancer Institute (NCI)NIH | 2 | Jul 31, 2026 | clinicaltrials |
| NCT04912765 | Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC | recruiting | Phase 2 | 60 | National Cancer Centre, SingaporeOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT05217446 | A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer(SEAMARK) | active not recruiting | Phase 2 | 108 | PfizerINDUSTRY | 15 | Jul 31, 2026 | clinicaltrials |
| NCT05691491 | Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness | recruiting | Phase 1 / Phase 2 | 42 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT04657068 | A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 542 | Artios Pharma LtdINDUSTRY | 4 | Jul 30, 2026 | clinicaltrials |
| NCT07736495 | Protective Role of Alpha-Lipoic Acid in Chemotherapy-Induced Mucositis | recruiting | Phase 2 / Phase 3 | 50 | Ain Shams UniversityOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT03526835 | A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 560 | Merus B.V.INDUSTRY | 7 | Jul 29, 2026 | clinicaltrials |
| NCT05024097 | A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer.(PANTHER) | recruiting | Phase 2 | 43 | Weill Medical College of Cornell UniversityOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT05009069 | A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer | active not recruiting | Phase 2 | 58 | Hoffmann-La RocheINDUSTRY | 1 | Jul 28, 2026 | clinicaltrials |
| NCT06321081 | ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC | recruiting | Phase 2 | 60 | Beijing HospitalOTHER_GOV | 1 | Jul 28, 2026 | clinicaltrials |
| NCT06493019 | Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer | recruiting | Phase 2 | 23 | Dustin DemingOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT06835387 | Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors | recruiting | Phase 2 | 36 | Tiago Biachi de CastriaOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT07411599 | Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out (KO) Therapy For Colorectal Cancer-Related Peritoneal Carcinomatosis: A Phase 1/2 Trial ("Chip-CRC Trial") | recruiting | Phase 1 / Phase 2 | 28 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT07580339 | Combining DCSZ11 With Radiation and Chemotherapy as Neoadjuvant Treatment for pMMR Locally Advanced Rectal Cancer | not yet recruiting | Phase 2 | 30 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT02595424 | Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas | active not recruiting | Phase 2 | 67 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Jul 27, 2026 | clinicaltrials |
| NCT05253846 | Short-course Radiotherapy Followed by Consolidation Chemotherapy. 2021-001206-29(ShorTrip) | active not recruiting | Phase 2 | 63 | Gruppo Oncologico del Nord-OvestOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT07104604 | Study on the Efficacy and Safety of Neoadjuvant Radiotherapy Combined With Tislelizumab, Liposomal Irinotecan, and Capecitabine in the Treatment of pMMR Locally Advanced Rectal Adenocarcinoma With Low Rectal Involvement | recruiting | Phase 2 | 51 | Affiliated Cancer Hospital of Shantou University Medical CollegeOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT07724223 | Fruquintinib Plus Anti-EGFR Antibody for Third-Line Treatment of RAS Wild-Type mCRC | recruiting | Phase 2 | 46 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT05609370 | A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer | active not recruiting | Phase 1 / Phase 2 | 113 | BeiGeneINDUSTRY | 4 | Jul 23, 2026 | clinicaltrials |
| NCT07133750 | PM8002 (BNT327) in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer | recruiting | Phase 2 | 100 | Biotheus Inc.INDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT03485209 | Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors(innovaTV 207) | active not recruiting | Phase 2 | 350 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 7 | Jul 22, 2026 | clinicaltrials |
| NCT03796884 | Linaclotide in Treating Patients With Stages 0-3 Colorectal Cancer | active not recruiting | Phase 2 | 150 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT07718490 | Immunotheray Combined With Simvastatin and Target Therapy and Chemotharepy for Advanced Colorectal Cancer | recruiting | Phase 2 | 43 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT06215677 | Neoadjuvant Immunotherapy for T4 dMMR Colon Cancer(NITDC) | active not recruiting | Phase 2 | 18 | Peking Union Medical College HospitalOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT07281768 | Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer | recruiting | Phase 2 | 66 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT07714447 | Efficacy and Safety of Tunlametinib Combination Therapy in the Treatment of Second-line and Above Metastatic Colorectal Cancer | not yet recruiting | Phase 2 | 91 | Sun Yat-sen UniversityOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT04599140 | SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial | active not recruiting | Phase 1 / Phase 2 | 51 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT06907342 | Testing a Functional Precision Medicine Approach to Select Chemotherapy for Metastatic Colorectal Cancer (COSENSE-1)(COSENSE-1) | recruiting | Phase 2 | 148 | St. Olavs HospitalOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT03087071 | Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer | active not recruiting | Phase 2 | 59 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT03599752 | Chemotherapy and/or Metastasectomy in Treating Patients With Metastatic Colorectal Adenocarcinoma With Lung Metastases | active not recruiting | Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 2 | Jul 16, 2026 | clinicaltrials |
| NCT05705492 | Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer | recruiting | Phase 2 | 66 | OHSU Knight Cancer InstituteOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06948448 | A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer | recruiting | Phase 2 | 144 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 6 | Jul 16, 2026 | clinicaltrials |
| NCT06129604 | Pilot Window of Opportunity Trial (POET) | active not recruiting | Phase 2 | 10 | University of OklahomaOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT06580002 | Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial | recruiting | Phase 2 | 75 | University of California, IrvineOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT05726864 | A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors(AMPLIFY-7P) | active not recruiting | Phase 1 / Phase 2 | 158 | Elicio TherapeuticsINDUSTRY | 1 | Jul 10, 2026 | clinicaltrials |
| NCT06695845 | A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors | recruiting | Phase 2 | 200 | Jazz PharmaceuticalsINDUSTRY | 3 | Jul 10, 2026 | clinicaltrials |
| NCT05054959 | Consolidation Versus Induction Chemotherapy in Total Neoadjuvant Therapy of Rectal Cancer With High Risk for Recurrence(ICONA) | active not recruiting | Phase 2 | 62 | Institute of Oncology LjubljanaOTHER | 1 | Jul 9, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 7, 2026source: clinicaltrials